HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.

Lancet. 1984 Dec 22;2(8417-18):1444-6. Unique Identifier : AIDSLINE MED/85085183
Melbye M; Froebel KS; Madhok R; Biggar RJ; Sarin PS; Stenbjerg S; Lowe GD; Forbes CD; Goedert JJ; Gallo RC; et al

Abstract: 77 Scottish haemophiliacs and 22 Danish haemophiliacs were serologically tested for antibodies to human T-cell leukaemia virus III (HTLV-III). Since 1979 the Scottish patients had been treated largely with factor VIII concentrate produced in Scotland, whereas all but 2 of the Danish patients had received both locally prepared concentrate and commercial concentrate made from US donor material. 15.6% of Scottish and 59.1% of Danish haemophiliacs were antibody positive (p less than 0.001). None of 11 haemophiliacs not treated in the period 1979-84 was seropositive. 2 (6.7%) of 30 subjects who had been treated with locally produced concentrate only were antibody positive, compared with 23 (39.7%) of 58 subjects who had been treated with commercial concentrate. Among 52 users of both commercially and locally produced factor VIII concentrate, seropositivity was directly correlated with the consumption of commercial concentrate (p less than 0.001) but not locally produced material. These data indicate that European haemophiliacs were exposed to HTLV-III via some factor VIII concentrates obtained from the USA.
Keywords: Adolescence Adult Aged Antibodies, Viral/*ANALYSIS Case Report Comparative Study Denmark Factor VIII/*THERAPEUTIC USE Hemophilia/*IMMUNOLOGY/THERAPY Human HTLV-BLV Viruses/*IMMUNOLOGY Male Middle Age Risk Scotland United States JOURNAL ARTICLE

KWDadolescenceadultagedantibodies,viral/KWDanalysiscasereportcomparativestudydenmarkfactorviii/KWDtherapeuticusehemophilia/KWDimmunology/therapyhumanhtlv-blvviruses/KWDimmunologymalemiddleageriskscotlandunitedstatesjournalarticle
850430
M8540069

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .